8/1/12 Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, August 31, 2012

Wiki Encyclopedia - ovarian cancer



http://en.m.wikipedia.org/wiki/Ovarian_cancer


Sent from my iPhone

New Anticancer Drugs Associated With Increased Toxicity



Medscape: Risk for Substance Abuse in...



Robotic Surgery for Gynaecologic Cancer



http://www.ncbi.nlm.nih.gov/m/pubmed/22932780/?i=6&from=ovarian%20cancer


Sent from my iPhone

Intake of omega-3 and omega-6 fatty acids and risk of ovarian cancer.



http://www.ncbi.nlm.nih.gov/m/pubmed/22933054/?i=3&from=ovarian%20cancer


Sent from my iPhone

Stage at diagnosis and ovarian cancer survival: Evidence from the International Cancer Benchmarking Partnership




Stage at diagnosis and ovarian cancer survival: Evidence from the International Cancer Benchmarking Partnership

Publication year: 2012
Source:Gynecologic Oncology, Volume 127, Issue 1
Camille Maringe, Sarah Walters, John Butler, Michel P. Coleman, Neville Hacker, Louise Hanna, Berit J. Mosgaard, Andy Nordin, Barry Rosen, Gerda Engholm, Marianne L. Gjerstorff, Juanita Hatcher, Tom B. Johannesen, Colleen E. McGahan, David Meechan, Richard Middleton, Elizabeth Tracey, Donna Turner, Michael A. Richards, Bernard Rachet
Objective We investigate what role stage at diagnosis bears in international differences in ovarian cancer survival. Methods Data from population-based cancer registries in Australia, Canada, Denmark, Norway, and the UK were analysed for 20,073 women diagnosed with ovarian cancer during 2004–07. We compare the stage distribution between countries and estimate stage-specific one-year net survival and the excess hazard up to 18months after diagnosis, using flexible parametric models on the log cumulative excess hazard scale. Results One-year survival was 69% in the UK, 72% in Denmark and 74–75% elsewhere. In Denmark, 74% of patients were diagnosed with FIGO stages III–IV disease, compared to 60–70% elsewhere. International differences in survival were evident at each stage of disease; women in the UK had lower survival than in the other four countries for patients with FIGO stages III–IV disease (61.4% vs. 65.8–74.4%). International differences were widest for older women and for those with advanced stage or with no stage data. Conclusion Differences in stage at diagnosis partly explain international variation in ovarian cancer survival, and a more adverse stage distribution contributes to comparatively low survival in Denmark. This could arise because of differences in tumour biology, staging procedures or diagnostic delay. Differences in survival also exist within each stage, as illustrated by lower survival for advanced disease in the UK, suggesting unequal access to optimal treatment. Population-based data on cancer survival by stage are vital for cancer surveillance, and global consensus is needed to make stage data in cancer registries more consistent.

Highlights

► Where overall survival is low, this is partly attributable to a more adverse stage distribution. ► Stage-specific survival still differs widely between jurisdictions. ► Global cancer surveillance requires consensus on data about diagnostic investigations and stage.


Sent from my iPhone

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma




Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

Publication year: 2012
Source:Gynecologic Oncology, Volume 127, Issue 1
Ursula A. Matulonis, Sudarshan Sharma, Sharad Ghamande, Michael S. Gordon, Salvatore A. Del Prete, Isabelle Ray-Coquard, Elzbieta Kutarska, Hua Liu, Howard Fingert, Xiaofei Zhou, Hadi Danaee, Russell J. Schilder
Objectives Aurora A kinase (AAK), a key mitotic regulator, is implicated in the pathogenesis of several tumors, including ovarian cancer. This single-arm phase II study assessed single-agent efficacy and safety of the investigational AAK inhibitor MLN8237 (alisertib), in patients with platinum-refractory or ‐resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Methods Adult women with malignant, platinum-treated disease received MLN8237 50mg orally twice daily for 7days plus 14days' rest (21-day cycles). The primary endpoint was combined objective tumor response rate per Response Evaluation Criteria in Solid Tumors (RECIST) and/or CA-125 criteria. Secondary endpoints included response duration, clinical benefit rate, progression-free survival (PFS), time-to-progression (TTP), and safety. Results Thirty-one patients with epithelial ovarian (n=25), primary peritoneal (n=5), and fallopian tube carcinomas (n=1) were enrolled. Responses of 6.9–11.1month duration were observed in 3 (10%) patients with platinum-resistant ovarian cancer. Sixteen (52%) patients achieved stable disease with a mean duration of response of 2.86months and which was durable for ≥3months in 6 (19%). Median PFS and TTP were 1.9months. Most common drug-related grade ≥3 adverse events were neutropenia (42%), leukopenia (23%), stomatitis, and thrombocytopenia (each 19%); 6% reported febrile neutropenia. Conclusions These data suggest that MLN8237 has modest single-agent antitumor activity and may produce responses and durable disease control in some patients with platinum-resistant ovarian cancer. MLN8237 is currently undergoing evaluation in a phase I/II trial with paclitaxel in recurrent ovarian cancer.

Highlights

► Aurora A kinase may have a role in the pathobiology of ovarian cancer. ► Investigational agent MLN8237 (alisertib) is an oral Aurora A kinase inhibitor. ► MLN8237 has modest antitumor activity in platinum-resistant ovarian cancer.


Sent from my iPhone

Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls




Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls

Publication year: 2012
Source:Gynecologic Oncology, Volume 127, Issue 1
Marjanka J.J.M. Mingels, Thijs Roelofsen, Jeroen A.W.M. van der Laak, Joanne A. de Hullu, Maaike A.P.C. van Ham, Leon F.A.G. Massuger, Johan Bulten, Mijke Bol
Objective A precursor lesion for ovarian carcinoma, tubal intraepithelial carcinoma (TIC), has been identified in BRCA-mutation carriers undergoing prophylactic bilateral salpingo-oophorectomy (pBSO). Other lesions were also identified in fallopian tubes, but different terminology, interpretation, and lack of knowledge of normal epithelium, have hampered to unravel their possible role in carcinogenesis. The aim of this study is to classify tubal epithelial lesions in BRCA-mutation carriers and controls to enable comparison of prevalence, area of localization, and possible malignant potential. Methods Two hundred twenty-six BRCA1/2-mutation carriers were included; ovaries and fallopian tubes, embedded completely, were reviewed. Controls included 105 women who underwent BSO for non-malignant reasons. Tubal epithelial lesions included the following categories: hyperplasia, minor epithelial atypia, TIC, and invasive carcinoma. Results Tubal neoplasia was identified in 7.1% (invasive carcinoma, 0.9%; TIC, 6.2%) of BRCA-mutation carriers compared to none in controls (p =0.004, Fisher's exact test). Hyperplasia and minor epithelial atypia were identified in 41.6% BRCA-mutation carriers and compared to 58.1% in controls (p =0.005, Pearson's chi square). Invasive carcinoma and TIC showed preference for the fimbrial ends (p =0.027, Pearson's chi square), while hyperplasia and minor epithelial atypia displayed more variation in localization. Conclusions Invasive tubal carcinoma and TIC were limited to BRCA-mutation carriers, whereas hyperplasia and minor epithelial atypia were commonly found in both BRCA-mutation carriers and controls. It is suggested that hyperplasia and minor atypia represent variations of normal tubal epithelium instead of premalignant lesions. Furthermore, total salpingectomy is strongly recommended as most but not all TIC occurred in the fimbriae.

Highlights

►Tubal epithelium was reviewed in the largest cohort to date of both BRCA-mutation carriers and controls. ►Tubal neoplasia was limited to BRCA-mutation carriers, whereas tubal hyperplasia and minor atypia were more often identified in controls. ►Total salpingectomy rather than only fimbriectomy is essential for prophylactic tubal and ovarian cancer prevention.


Sent from my iPhone

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study




Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Publication year: 2012
Source:Gynecologic Oncology, Volume 127, Issue 1
Russell J. Schilder, William E. Brady, Heather A. Lankes, James V. Fiorica, Mark S. Shahin, Xun C. Zhou, Robert S. Mannel, Harsh B. Pathak, Wei Hu, R. Katherine Alpaugh, Anil K. Sood, Andrew K. Godwin
Objectives Preclinical data suggest an important role for the sarcoma proto-oncogene tyrosine kinase (SRC) in the oncogenesis of epithelial ovarian cancer (EOC) or primary peritoneal carcinoma (PPC). The Gynecologic Oncology Group (GOG) conducted a Phase II trial to evaluate the efficacy and safety of dasatinib, an oral SRC-family inhibitor in EOC/PPC, and explored biomarkers for possible association with clinical outcome. Methods Eligible women had measurable, recurrent or persistent EOC/PPC and had received one or two prior regimens which must have contained a platinum and a taxane. Patients were treated with 100mg orally daily of dasatinib continuously until progression of disease or adverse effects prevented further treatment. Primary endpoints were progression-free survival (PFS) ≥6months and response rate. Serial plasma samples were assayed for multiple biomarkers. Circulating free DNA was quantified as were circulating tumor and endothelial cells. Results Thirty-five (35) patients were enrolled in a two-stage sequential design. Of the 34 eligible and evaluable patients, 20.6% (90% confidence interval: 10.1%, 35.2%) had a PFS ≥6months; there were no objective responses. Grade 3–4 toxicities were gastrointestinal (mostly nausea and emesis; n =4), pulmonary (dyspnea and/or pleural effusion; n =4) and pain (n =5), and infrequent instances of anemia, malaise, insomnia, rash, and central nervous system hemorrhage. Lack of clinical activity limited any correlation of biomarkers with outcome. Conclusion Dasatinib has minimal activity as a single-agent in patients with recurrent EOC/PPC.

Highlights

► No objective responses with 7 of 34 patients had PFS ≥6months. ► The agent was well tolerated with the major toxicities being grade 3 nausea/emesis, pain and pulmonary. ► No detectable relationships between clinical outcome and biomarkers.


Sent from my iPhone

Height, weight, BMI and ovarian cancer survival




Height, weight, BMI and ovarian cancer survival

Publication year: 2012
Source:Gynecologic Oncology, Volume 127, Issue 1
Joanne Kotsopoulos, Joel R.K. Moody, Isabel Fan, Barry Rosen, Harvey A. Risch, John R. McLaughlin, Ping Sun, Steven A. Narod
Objectives Ovarian cancer is a highly fatal gynecologic malignancy. Prognosis is primarily based on clinicopathologic features. There is interest in the role of modifiable factors including overweight and obesity, although data to date have been inconclusive. Here we evaluate the relationship between body size and ovarian cancer survival among 1423 women diagnosed with epithelial ovarian cancer in a large population-based study. Methods Information on risk factors and characteristics was collected by telephone. Vital status was determined both by computerized record-linkage and by chart review. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for height, weight and body mass index (BMI) in association with ovarian cancer-specific mortality. Results Height, weight and BMI 5years prior to diagnosis did not significantly predict ovarian cancer survival in this study. The HR for ovarian cancer-specific mortality for women with a weight of >61kg compared with >50–55kg was 0.91 (95%CI 0.71–1.20). The HR among women with a BMI≥30kg/m2 compared to 18.5– <25kg/m2 was 1.11 (95%CI 0.87–1.42). These findings did not vary by histologic subtype. Conclusions Our results do not support a role of height, adult weight or adiposity in ovarian cancer prognosis.

Highlights

► The role of modifiable host factors including overweight and obesity on ovarian cancer prognosis is not clear. ► We evaluated the relationship between body size and ovarian cancer survival among 1423 women diagnosed with epithelial ovarian cancer. ► Our results do not support a role of height, weight or adiposity in ovarian cancer prognosis.


Sent from my iPhone

The utilization of palliative care in gynecologic oncology patients near the end of life




The utilization of palliative care in gynecologic oncology patients near the end of life

Publication year: 2012
Source:Gynecologic Oncology, Volume 127, Issue 1
Janelle Fauci, Kellie Schneider, Christy Walters, Jonathan Boone, Jenny Whitworth, Ellie Killian, J. Michael Straughn
Background Palliative and supportive care services provide excellent care to patients near the end of life. It is estimated that enrollment in such services can reduce end-of-life costs; however, there is limited data available regarding the impact of palliative services in end-of-life care in gynecologic oncology patients. We examined the use of palliative services in gynecologic oncology patients during the last six months of life. Methods After IRB approval, a retrospective chart review of patients with a diagnosis of a gynecologic malignancy who died between June 2007 and June 2010 was performed. Abstracted data included demographics, admission and procedural history, use of anti-cancer therapy, and palliative care utilization during the last six months of life. Results 268 patients were identified. Most patients were white (76.9%) and had ovarian cancer (56.7%). During the last six months of life, 155 (57.8%) patients underwent anti-cancer therapy with chemotherapy, 19 (7.1%) patients were treated with radiation therapy, and 17 patients (6.3%) underwent treatment with both. 218 patients (81.3%) had at least one admission during this time (range 0–14). The most common reason for admission was gastrointestinal complaints (37.1%), followed by admissions for procedures (18.3%). The median time between the last admission and death was 32days. 157 patients (58.6%) underwent at least one procedure during the last six months of life (range 0–11). The most common procedure performed was paracentesis (22.6%). 198 (73.9%) patients died at home or in a palliative care unit. 189 (70.5%) patients were referred to hospice or palliative care. 3.2% underwent a procedure or treatment with chemotherapy or radiation after hospice enrollment. The median time between hospice enrollment and death was 22days. 55% of patients were enrolled in hospice less than 30days before death. Of the 79 patients not referred to hospice, only 16.5% had documentation of refusing hospice services. Conclusions During the last six months of life, the majority of gynecologic oncology patients receive anticancer therapy and many have repeated hospital admissions. While the majority of patients are referred for palliative care, it appears that most patients spend less than 30days on hospice. Earlier referral could decrease the number of hospital admissions and procedures while providing invaluable support during this end of life transition.

Highlights

► Enrollment in hospice may dramatically reduce the number of admissions and procedures performed during the last weeks of life. ► The majority of patients are ultimately referred to hospice, however most patients were referred less than 30days before death. ► Discussing end-of-life issues with pat...


Sent from my iPhone

Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy




Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy

Publication year: 2012
Source:Gynecologic Oncology, Volume 127, Issue 1

Objectives To examine the distribution and outcomes of recurrent disease in patients with ovarian, fallopian tube and peritoneal cancers after optimal cytoreduction and adjuvant intraperitoneal (IP) chemotherapy. Methods All patients diagnosed with ovarian, fallopian tube, or peritoneal cancer between 2004 and 2009 who underwent optimal cytoreductive surgery and received adjuvant intravenous (IV) and IP chemotherapy with paclitaxel and a platinum-based agent were eligible. Age, performance status, tumor origin, stage, and grade were recorded. First recurrences were identified using CA125 values, radiographic studies, operative notes, and pathology reports. Sites of recurrence were classified as intraperitoneal (IP), extraperitoneal (EP) or distant. Kaplan–Meier estimates and Cox multivariate regression models were used to assess the associations between recurrent disease distribution and progression-free survival (PFS) and overall survival (OS). Results One hundred forty-three patients met the criteria for inclusion. The majority were Stage III (86%) and serous histology (77%). Eighty-four (58.7%) received IV/IP paclitaxel/cisplatin per GOG-172 and 59 (41.3%) received IV/IP paclitaxel/carboplatin. Seventy-two percent completed 6cycles. Ninety (62.9%) patients manifested a recurrence. One-hundred twelve sites of recurrence were identified with 70 (62.5%) IP and 42 (37.5%) EP and distant sites. Nineteen (21%) recurred in more than one site, i.e. both IP and EP locations. Site of recurrence did not impact OS, however, patients who recurred in multiples sites had significantly worse OS (p<0.001). Conclusion Approximately 40% of patients treated with IP chemotherapy have a first recurrence outside the peritoneal cavity. Though site of recurrence did not affect OS those with multi-focal recurrence demonstrate worse survival.

Highlights

► 41% of patients manifest a first recurrence outside the peritoneal cavity after IP chemotherapy. ► 72% of patients completed all 6cycles of IP chemotherapy. ► Patients that recur in multiple locations manifest a worse overall survival

Trastuzumab (Herceptin) tied to increased heart failure risk



Trastuzumab (Herceptin) tied to increased heart failure risk


email
print
share

Clinical

Last Updated: 2012-08-30 18:35:16 -0400 (Reuters Health)

NEW YORK (Reuters Health) - The chemotherapy combination of anthracycline and trastuzumab (Herceptin) increased women's risk of heart failure sevenfold in a new retrospective cohort study - and anthracycline wasn't all to blame.

The risk of heart failure or cardiomyopathy "was highly increased in patients treated with trastuzumab alone," the researchers reported in a paper released August 30 by the Journal of the National Cancer Institute.

Earlier randomized controlled trials also showed a link between the drugs and heart failure risk. But researchers said those risks may have been underestimated because the studies were limited to younger women without comorbidities.

"The rates of heart failure might actually be higher than what clinical trials have estimated to be associated with these drugs," lead researcher Erin Bowles from Group Health Research Institute in Seattle, Washington told Reuters Health....




Sent from my iPhone

Thursday, August 30, 2012

Agents to prevent chemo-induced nausea lacking: study - - ModernMedicine



http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Agents-to-prevent-chemo-induced-nausea-lacking-stu/ArticleNewsFeed/Article/detail/786880?contextCategoryId=40139&ref=25


Sent from my iPhone

JCO : Journal of Clinical Oncology Blindness: Looking but Not Seeing (the art of oncology)



http://m.jco.ascopubs.org/content/30/25/3141.short?rss=1


Sent from my iPhone

Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review



Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review





Sent from my iPhone

Access : Phase I oncology trials incorporating patient choice of dose : British Journal of Cancer



http://www.nature.com/bjc/journal/vaop/ncurrent/full/bjc2012378a.html


Sent from my iPhone

Hormone replacement therapy use continue to fall - - ModernMedicine



http://www.modernmedicine.com/modernmedicine/Endocrinology/Hormone-replacement-therapy-use-continue-to-fall/ArticleNewsFeed/Article/detail/786702?contextCategoryId=40139&ref=25


Sent from my iPhone

Modeling the Longitudinal Transitions of Performance Status in Cancer Outpatients: Time to Discuss Palliative Care




Modeling the Longitudinal Transitions of Performance Status in Cancer Outpatients: Time to Discuss Palliative Care

Publication year: 2012
Source:Journal of Pain and Symptom Management
Rinku Sutradhar, Hsien Seow, Craig Earle, Deborah Dudgeon, Clare Atzema, Amna Husain, Doris Howell, Ying Liu, Jonathan Sussman, Lisa Barbera
Context Understanding the longitudinal transitions of performance status among persons with cancer can assist providers in determining the appropriate time to initiate palliative care support. Objectives To model longitudinal transitions of the performance status in cancer outpatients, to determine the probabilities of improvement and deterioration in performance status over time, and to evaluate the factors associated with rates of transitions. Methods This population-based, retrospective, cohort study comprised adult outpatients diagnosed with any type of cancer and assessed for performance status throughout their observation period using the Palliative Performance Scale (PPS; scale 0–100; 0 indicates death). At every PPS assessment, patients were assigned to one of four states: stable state (PPS score 70–100), transitional state (PPS score 40–60), end-of-life state (PPS score 10–30), or dead. A Markov multistate model under the presence of interval censoring was used to examine the rate of state-to-state transitions. Results There were 11,374 patients representing nearly 71,000 assessments. Patients with lung cancer in the transitional state had a 27.7% chance of being dead at the end of one month vs. 17.5% in patients with breast cancer. The average time spent in the transitional state was 6.6 weeks for patients diagnosed with gastrointestinal cancer vs. 8.8 weeks for patients with breast cancer. The rate at which one moves from the transitional state to death was higher for patients with lung cancer than those with breast cancer. Conclusion We estimated the probability and direction of change in performance status in cancer outpatients. Entry into the transitional state may serve as an indicator for referral for palliative care support. Mean end-of-life sojourn times are too short to allow meaningful integration of palliative care.



Sent from my iPhone

Constipation in Palliative Care: What Do We Use as Definitions and Outcome Measures?




Constipation in Palliative Care: What Do We Use as Definitions and Outcome Measures?

Publication year: 2012
Source:Journal of Pain and Symptom Management

Context 
Advances in the management of constipation in palliative care remain hindered by the lack of agreed-upon diagnostic criteria. Objectives The objective of this work was to emphasize this issue by systematically examining the eligibility and primary outcome measures in studies of constipation in the hospice and palliative care population. Methods A palliative care-specific electronic literature search was undertaken using the validated domain filter "palliative care" and topic filter "constipation" in CareSearch (www.caresearch.com.au), which interrogates PubMed in real time (1965–2011). Studies were included if they were primary reports of the treatment of constipation in a palliative care setting. Articles could be prospective or retrospective; randomized controlled trials, cohort studies, or case series. Results Twenty articles on the palliative care population were included in which there were six different definitions of constipation. Only 12 of 20 articles used their cited definitions of constipation as the studies' primary outcome measures and four of four blinded randomized controlled trials. Articles that used the time between bowel actions or the use of laxatives as the definition of constipation were most likely to report outcomes based on these criteria. Conclusion Constipation is a significant problem in palliative care; however, not having an agreed-upon definition limits research initiatives and the ability to apply these results clinically to people with constipation. Four domains are suggested as pivotal to the diagnosis: any life-long history of constipation (using the Rome Criteria), evaluation of physical changes that may cause or worsen constipation, the subjective sensation (such as feelings incomplete defecation or bloating or fullness), and objective changes (such as frequency or consistency of stools).

Safety Alerts for Human Medical Products > Baxter Healthcare Corporation, Automix Automated Nutrition Compounder Systems: Class I Recall - Risk of Fluid Entry into Device Keypads ( TPN )



http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm317448.htm?source=govdelivery


Sent from my iPhone

Proportion cured models applied to 23 cancer sites in norway.



Proportion cured models applied to 23 cancer sites in norway.


Abstract


BACKGROUND: Statistical cure is reached when a group of patients has the same mortality as cancer-free individuals. Cure models predict the cured proportion and the median survival of fatal cases. Cure models have seldom been applied and tested systematically across all major cancer sites.

METHODS: Incidence and follow-up data on 23 cancer sites recorded at the Cancer Registry of Norway 1963-2007 were obtained. Mixture cure models were fitted to obtain trends and up-to-date estimates (based on period approach) assuming cured and uncured groups exist.

RESULTS: The model converged for cancers of the mouth and pharynx, oesophagus, stomach, colon, rectum, liver, gallbladder, pancreas, lung and trachea, ovary, kidney, bladder, CNS, non-Hodgkin lymphoma (only for males) and leukaemia. The proportion of cured patients increased 1963-2002 for both sexes, with the largest changes (in %) seen for leukaemia (46.4 and 46.7) and CNS (35.9, 42.0), males given first. Median survival time for the uncured cases increased for colon and rectal cancer, and there was a three- fold increase in median survival time for patients with fatal ovarian cancers. Cancers of bladder and CNS had the highest up-to-date proportion cured (in %) (67.4 and 64.0, respectively), pancreas and liver were amongst the lowest (5.7 and 9.9, respectively).

CONCLUSION: Cure models are useful when monitoring progress in cancer care, but must be applied and interpreted with caution. The absolute estimates of the cure proportion are speculative, and should not be calculated where cure is not medically anticipated. © 2012 Wiley Periodicals, Inc.




Sent from my iPhone

Anticipatory Loss and Early Mastectomy for Young Female BRCA1/2 Mutation Carriers.



Anticipatory Loss and Early Mastectomy for Young Female BRCA1/2 Mutation Carriers.

Abstract

Young women who carry BRCA1/2 mutations face difficult decisions in managing their hereditary breast/ovarian cancer risk. Through this National Cancer Institute study, we sought to understand the process by which some young women choose risk-reducing bilateral mastectomy (RRBM) instead of alternative risk-management options. Data indicate that electing to undergo RRBM, although difficult, is experienced as a way to sidestep potentially devastating outcomes, such as stressful and costly high-risk screening, chemotherapy or radiation, or putting loved ones through the challenges of a cancer diagnosis. The decision to pursue RRBM is often the product of screening fatigue, encouragement from loved ones, and/or a sense of urgency to put one's high-risk period behind one. By understanding how young carriers make decisions about surgical risk reduction, providers can better guide, counsel, and support patients in the important tasks surrounding this life-changing medical decision, thereby helping to increase the duration and quality of their lives.

PMID

 22927701 [PubMed - as supplied by publisher]



Sent from my iPhone

PDF: Emerging treatment options for management of malignant ascites in patients with ovarian cancer



Emerging treatment options for management of malignant ascites in patients with ovarian cancer





Sent from my iPhone

Emerging treatment options for management of malignant ascites in patients with ovarian cancer.



Emerging treatment options for management of malignant ascites in patients with ovarian cancer.

Abstract

Malignant ascites affects approximately 10% of patients with recurrent epithelial ovarian cancer and is associated with troublesome symptoms, including abdominal pressure and distension, dyspnea, bloating, pelvic pain, and bowel/bladder dysfunction. To date, no effective therapy has been identified for the treatment of malignant ascites in patients with recurrent, advanced ovarian cancer. In this article, we discuss currently existing options for the treatment of ascites associated with ovarian cancer, and review the literature as it pertains to novel, targeted therapies. Specifically, preclinical and clinical trials exploring the use of the antiangiogenic agents, bevacizumab and vascular endothelial growth factor-trap, as well as the nonangiogenic agent, catumaxomab, will be reviewed. Despite current limitations in treatment, knowledge regarding management options in the palliation of ascites is critical to practicing physicians. Ultimately, as with all novel therapies, symptom relief and treatment goals must be weighed against patient discomfort and potentially significant adverse events.




Sent from my iPhone

Oophorectomy: the debate between ovarian conservation and elective oophorectomy.



Oophorectomy: the debate between ovarian conservation and elective oophorectomy.

ABSTRACT: Ovarian cancer remains the fifth deadliest cancer among women because of its early asymptomatic nature and lack of efficacious screening methods, leading to frequent late-stage diagnosis. Elective oophorectomy is an option for women undergoing benign hysterectomy as a means of reducing their ovarian cancer risk. Benefits also include reduced risk of repeat surgical operation due to adnexal masses and reduced anxiety related to perceived risk of ovarian and breast cancer. The potential negative side effects of elective oophorectomy, such as decreased cognition and sexual function and increased risk of osteoporosis and cardiac mortality, offer support for ovarian conservation. The implications of this elective procedure and the possible consequences without it require physicians to review the pros and cons with patients in light of the patient's individual circumstances and ovarian cancer risk.

PMID

 22929033 [PubMed - as supplied by publisher]



Sent from my iPhone

Changes in short-term health-related quality of life in women undergoing gynecologic oncologic laparotomy: an associated factor analysis.



Changes in short-term health-related quality of life in women undergoing gynecologic oncologic laparotomy: an associated factor analysis.


Journal

Support Care Cancer. 2012 Aug 29

Abstract

PURPOSE: The primary purpose of this study is to evaluate health-related quality of life (HR-QOL) of gynecologic cancer patients undergoing laparotomy.

METHODS: Women who underwent laparotomy by gynecologic cancer completed the European Organization for Research and Treatment of Cancer (EORTC) Quality of life questionnaires (QLQ-C30 and QLQ-OV28) presurgery and at 1 month.

RESULTS: Of the 181 women studied between January 2007 and March 2008, 116 women (64.1 %) had ovarian cancer, 27 (14.9 %) had cervical cancer, and 29 (16.0 %) had endometrial cancer. By 1 month post-surgery, there was a significant decrease in HR-QOL on the global, abdominal/gastrointestinal (GI) score, body image, chemotherapy side effects, and other single items of the OV28 questionnaire, as well as on physical, role and social functioning, fatigue, nausea and vomiting, pain, insomnia, constipation, appetite loss, and financial difficulties items on C30 questionnaires. Emotional functioning on C30 questionnaires was significantly improved 1 month after surgery. The majority of these items persisted 1 month after surgery only in patients with ovarian cancer. Abdominal/GI score on OV28 questionnaires as well as role and physical functioning on C30 questionnaires were significantly lower between baseline and postsurgical HR-QOL in women with other gynecologic malignancies.

CONCLUSION: The results suggest a significant impact of HR-QOL among gynecologic cancer patients 1 month after laparotomy, particularly among those with ovarian cancer.




Sent from my iPhone

CANDISC: NCI Trials Program Looks for Net Gains



NCI Trials Program Looks for Net Gains




Sent from my iPhone

Gender bias in leading scientific journals



http://www.sciencedaily.com/releases/2012/08/120830102851.htm?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+sciencedaily+%28ScienceDaily%3A+Latest+Science+News%29&utm_content=Google+Reader


Sent from my iPhone

CEU Bulletin, July 2012 | Cochrane Clinical Answers



Cochrane Clinical Answers

Wiley and the Cochrane Editorial Unit are working on a project to create a new product: Cochrane Clinical Answers (CCAs). CCAs are aimed at clinicians at the point of care, and they use evidence from Cochrane systematic reviews to create short answers to clinical questions. The content is developed by drawing out key information from Cochrane Reviews (an automated process), then a team of freelance clinicians (associate editors) and the CCA Editor use this evidence to create the clinical answers. All CCAs are then signed off by The Cochrane Library Editor-in-Chief, David Tovey.

We currently have 53 CCAs going through the editorial process, 32 of which have been signed off. Alongside the editorial work, the CCA website is being developed, and we are aiming for a clear, uncomplicated design that is easy and quick to use. Market testing of the site has been completed and Wiley is currently working to incorporate both market testing and CEU feedback. The site is due to launch later in the year and will be on display at the Cochrane Colloquium in Auckland. If Cochrane Review Groups would like to be involved in this project in any way, or if they have any questions, please do contact me.

Karen Pettersen (kpettersen@wiley.com), CCA editor




Sent from my iPhone

Chat With a Doctor: Ovarian Cancer — Health Hub from Cleveland Clinic



http://health.clevelandclinic.org/2012/08/chat-with-a-doctor-ovarian-cancer/?utm_source=rss&utm_medium=rss&utm_campaign=chat-with-a-doctor-ovarian-cancer


Sent from my iPhone

Am. J. Epid. - The Forgotten Griever: A Nationwide Follow-up Study of Mortality Subsequent to the Death of a Sibling



The Forgotten Griever: A Nationwide Follow-up Study of Mortality Subsequent to the Death of a Sibling




Sent from my iPhone

Fruit and vegetable intake and impact on pancreatic cancer....



".....Associations were similar for men and women separately and across studies. These results suggest that fruit and vegetable intake during adulthood is not associated with a reduced pancreatic cancer risk."

http://www.google.ca/reader/i/?source=mog&hl=en&gl=ca#stream/feed%2Fhttp%3A%2F%2Faje.oxfordjournals.org%2Frss%2Fcurrent.xml


Sent from my iPhone

Risks of Primary Extracolonic Cancers Following Colorectal Cancer in Lynch Syndrome



Risks of Primary Extracolonic Cancers Following Colorectal Cancer in Lynch Syndrome:

Background
Lynch syndrome is a highly penetrant cancer predisposition syndrome caused by germline mutations in DNA mismatch repair (MMR) genes. We estimated the risks of primary cancers other than colorectal cancer following a diagnosis of colorectal cancer in mutation carriers.

Methods
We obtained data from the Colon Cancer Family Registry for 764 carriers of an MMR gene mutation (316 MLH1, 357 MSH2, 49 MSH6, and 42 PMS2), who had a previous diagnosis of colorectal cancer. The Kaplan–Meier method was used to estimate their cumulative risk of cancers 10 and 20 years after colorectal cancer. We estimated the age-, sex-, country- and calendar period–specific standardized incidence ratios (SIRs) of cancers following colorectal cancer, compared with the general population.

Results
Following colorectal cancer, carriers of MMR gene mutations had the following 10-year risk of cancers in other organs: kidney, renal pelvis, ureter, and bladder (2%, 95% confidence interval [CI] = 1% to 3%); small intestine, stomach, and hepatobiliary tract (1%, 95% CI = 0.2% to 2%); prostate (3%, 95% CI = 1% to 5%); endometrium (12%, 95% CI = 8% to 17%); breast (2%, 95% CI = 1% to 4%); and ovary (1%, 95% CI = 0% to 2%). They were at elevated risk compared with the general population: cancers of the kidney, renal pelvis, and ureter (SIR = 12.54, 95% CI = 7.97 to 17.94), urinary bladder (SIR = 7.22, 95% CI = 4.08 to 10.99), small intestine (SIR = 72.68, 95% CI = 39.95 to 111.29), stomach (SIR = 5.65, 95% CI = 2.32 to 9.69), and hepatobiliary tract (SIR = 5.94, 95% CI = 1.81 to 10.94) for both sexes; cancer of the prostate (SIR = 2.05, 95% CI = 1.23 to 3.01), endometrium (SIR = 40.23, 95% CI = 27.91 to 56.06), breast (SIR = 1.76, 95% CI = 1.07 to 2.59), and ovary (SIR = 4.19, 95% CI = 1.28 to 7.97).

Conclusion
Carriers of MMR gene mutations who have already had a colorectal cancer are at increased risk of a greater range of cancers than the recognized spectrum of Lynch syndrome cancers, including breast and prostate cancers.

How Radiation Oncologists Would Disclose Errors: Results of a Survey of Radiation Oncologists and Trainees



How Radiation Oncologists Would Disclose Errors: Results of a Survey of Radiation Oncologists and Trainees:

Purpose: To analyze error disclosure attitudes of radiation oncologists and to correlate error disclosure beliefs with survey-assessed disclosure behavior.

Conclusions: The surveyed radiation oncologists chose to respond with full disclosure at a high rate, although ideal disclosure practices were not uniformly adhered to beyond the initial decision to disclose the occurrence of the error.

ongoing: (gyn cancers) ChemoFx® PRO - A Post-Market Data Collection Study - Full Text View - ClinicalTrials.gov



ChemoFx® PRO - A Post-Market Data Collection Study - Full Text View - ClinicalTrials.gov

ongoing: A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study - Full Text View - ClinicalTrials.gov



A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study - Full Text View - ClinicalTrials.gov

ongoing: Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer - Full Text View - ClinicalTrials.gov



Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer - Full Text View - ClinicalTrials.gov

An eClinical trial system for cancer that integrates with clinical pathways and electronic medical records



An eClinical trial system for cancer that integrates with clinical pathways and electronic medical records:

Background
Various information technologies currently are used to improve the efficiency of clinical trials. However, electronic medical records (EMRs) are not yet linked to the electronic data capture (EDC) system. Therefore, the data must be extracted from medical records and transcribed to the EDC system. Clinical pathways are planned process patterns that are used in routine clinical practice and are easily applicable to the medical care and evaluation defined in a trial protocol. However, few clinical pathways are intended to increase the efficiency of clinical trials.

Purpose
Our purpose is to describe the design and development of a new clinical trial process model that enables the primary use of EMRs in clinical trials by integrating clinical pathways and EMRs.

Methods
We designed a new clinical trial model that uses EMR data directly in clinical trials and developed a system to follow this model. We applied the system to an investigator-initiated clinical trial and examined whether all data were extracted correctly. At the protocol development stage, our model measures endpoints based on clinical pathways with the same diagnosis. Next, medical record descriptions and the format of the statistical data are defined. According to these observations, screens for entry of data, which are used both in clinical practice and for study, are prepared into EMRs with an EMR template, and screens are prepared for data checks on our EMR retrieval system (ERS). In an actual trial, patients are registered and randomly assigned to a protocol treatment. The protocol treatment is executed according to clinical pathways, and the data are recorded to EMRs using EMR templates. The data are checked by a local data manager using reports created by the ERS. After edit checks and corrections, the data are extracted by the ERS, archived in portable document format (PDF) with an electronic signature, and transferred in comma-separated values (CSV) format to a coordinating centre. At the coordinating centre, the data are checked, integrated, and made available for a statistical analysis.

Results
We verified that the data could be extracted correctly and found no unexpected problems.

Limitation
To execute clinical trials in our system, the EMR template and efficient ERSs are required. Additionally, to execute multi-institutional clinical trials, it is necessary to create templates appropriate for EMRs at all participating sites and for the coordinating centre to validate local templates and procedures.

Conclusion
We proposed and pilot tested a new eClinical trial model. Because our model is integrated with routine documentation of clinical practice and clinical trials, redundant data entries were avoided and the burden on the investigator was minimised. The reengineering of the clinical trial process would facilitate the establishment of evidence in the future.

Wednesday, August 29, 2012

Vancouver, BC: The Effect of Direct-to-Consumer Genetic Tests on Anticipated Affect and Health-Seeking Behaviors: A Pilot Survey | Abstract



The Effect of Direct-to-Consumer Genetic Tests on Anticipated Affect and Health-Seeking Behaviors: A Pilot Survey | Abstract

Gynecologic Oncology - Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer



Gynecologic Oncology - Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer

Abstract

Objectives

There is a lack of knowledge about the health care events experienced by individual patients that lead to a definitive diagnosis of ovarian cancer (OC). The goal of this study was to describe the various pathways and to identify an optimal path to accurate diagnosis.

Methods

Women who were referred to gynecologic oncology for a suspected OC were enrolled to this study. Medical records (MRs) from all health care providers were obtained from the time the patient recalled first suspecting a health issue through the time of diagnosis to build a decision tree model. A Monte Carlo simulation was conducted of 83,000 patients to identify the optimal pathway to reach diagnosis.

Results

In the Monte Carlo simulation, gynecologic oncologists and gynecologists accounted for the most efficient diagnosis in over 37.9% and 29.2% of suspected OC cases, respectively, in terms of the least amount of time to reach diagnosis. Gynecologic oncologists were further associated with the fewest health care visits needed to reach diagnosis in 37% of the simulation cases; however, 23% of trials were indifferent to any specific provider.

Conclusions

The decision tree provides a more comprehensive view of the complexity in reaching an accurate diagnosis of OC. This analysis was able to identify the health care utilization patterns that underlie the events that occur to reach an accurate diagnosis in the setting of a suspected OC, and was able to identify the most efficient pathways that utilize the fewest health care resources in the least amount of time.

Highlights

► The Monte Carlo simulation found differences in efficiency to reach diagnosis in terms of both time and fewest healthcare visits
► Gynecologic oncologists were the most rapid and efficient entry point for patients to reach diagnoses in the Monte Carlo simulation
► Many healthcare resources (provider visits, tests and assessments) are utilized in the absence of early detection strategies for ovarian cancer

2012 (understanding) Abdominal and Pelvic CT



Abdominal and Pelvic CT

Current Opinion in Oncology- The management of small-cell carcinomas of the gynecologic tract



http://mobile.journals.lww.com/co-oncology/_layouts/oaks.journals.mobile/abstractviewer.aspx?year=2012&issue=09000&article=00016


Sent from my iPhone

CEBP: Oophorectomy and Breast Cancer inBRCA Mutation Carriers—Letter




Oophorectomy and Breast Cancer inBRCA Mutation Carriers—Letter
 Authors

The article by Kotsopoulos and colleagues (1) shows that oophorectomy significantly decreased the incidence of breast cancer in carriers of deleterious BRCA mutations, with OR, 0.52 [95% confidence interval (CI), 0.40–0.66]. This is an important result. The authors, however, wrongly interpreted their results writing that "women who underwent surgical menopause had a 48% decrease in the risk of developing breast cancer." An OR, in fact, is a good estimate of the relative risk (i.e., the risk ratio) only if the disease is rare, but in mutation carriers, the disease is very frequent. The source population actually included about 4,000 cases of 5,000 women, a proportion fairly consistent with the estimated penetrance of BRCA mutations. With such a large proportion of cases in the source population, the unbiased risk ratio could be of the order of 0.67, corresponding to 33% decrease in breast cancer risk, still a major effect. The same flawed interpretation was present in several previous articles from the same group.

Disclosure of Potential Conflicts of Interest

There are no potential conflicts of interest.

  • Received May 18, 2012.
  • Accepted May 22, 2012.

Reference

  1.  



Sent from my iPhone

CEBP: Lipid Profiles and Risk of Breast and Ovarian Cancer in the Swedish AMORIS Study



http://m.cebp.aacrjournals.org/content/21/8/1381.short


Sent from my iPhone

BMJ Group blogs: BMJ » Blog Archive » Martin Wiseman, Kathryn Allen, and Rachel Thompson: Weighing the evidence on cancer prevention



http://blogs.bmj.com/bmj/2012/08/28/martin-wiseman-kathryn-allen-and-rachel-thompson-weighing-the-evidence-on-cancer-prevention/


Sent from my iPhone

ScienceDirect.com - Gynecologic Oncology - Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients




Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients


Abstract

Objective

The purpose of this study was to investigate the cost-effectiveness of prolonged prophylaxis with enoxaparin in high-risk surgical patients with ovarian cancer. In addition, we sought to quantify the impact of prolonged prophylaxis (PP) on the incidence of venous thromboembolism (VTE), its related complications, and overall patient survival.

Methods

A Markov decision analytic model was used to estimate the costs, resource allocation and outcomes associated with the prolonged use of enoxaparin, for a total of four weeks after surgery, in patients undergoing primary debulking surgery for stage IIIC ovarian cancer. We estimated incremental cost per quality-adjusted life-year (QALY) at one and five year intervals; the estimated reduction in VTE episodes, bleeding episodes, and survival at the five year interval for a simulated cohort of 10,000 women.

Results

The incremental cost effectiveness ratio (ICER) for prolonged prophylaxis (PP) was $5236/QALY and $-1462/QALY at one and five years respectively. For patients receiving PP, the model estimated a 12% reduction in the clinically evident VTE episodes and a higher five-year survival (31.61% vs. 29.96%; p < 0.0001). Resource allocation analysis reveals that 95% of initial investment cost of prolonged enoxaparin is recovered within one year.

Conclusions

In ovarian cancer patients undergoing open abdominal surgery, prolonged VTE prophylaxis not only improves patient outcomes, but is also a cost saving strategy when modeled over five years. A significant reduction in the episodes of VTE and a higher overall survival warrants consideration for the routine use of PP in this patient population.


Highlights

► Prolonged VTE prophylaxis is a cost saving strategy when modeled over five years in post-operative ovarian cancer patients. ► Our model estimates improved overall survival and decreased number of venous thromobembolic events with prolonged prophylaxis.

Keywords

  • Prolonged